Rebekah A Samangaya

Summary

Country: UK

Publications

  1. ncbi A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia
    Rebekah A Samangaya
    Maternal and Fetal Health Research Centre, St Mary s Hospital, Manchester, United Kingdom
    Hypertens Pregnancy 28:369-82. 2009
  2. ncbi Phosphodiesterase inhibitor effect on small artery function in preeclampsia
    Rebekah A Samangaya
    Maternal and Fetal Health Research Centre, St Mary s Hospital, Manchester, UK
    Hypertens Pregnancy 30:144-52. 2011

Collaborators

Detail Information

Publications2

  1. ncbi A randomised, double-blinded, placebo-controlled study of the phosphodiesterase type 5 inhibitor sildenafil for the treatment of preeclampsia
    Rebekah A Samangaya
    Maternal and Fetal Health Research Centre, St Mary s Hospital, Manchester, United Kingdom
    Hypertens Pregnancy 28:369-82. 2009
    ..To determine if the phosphodiesterase type 5 inhibitor sildenafil prolongs pregnancy in women with preeclampsia...
  2. ncbi Phosphodiesterase inhibitor effect on small artery function in preeclampsia
    Rebekah A Samangaya
    Maternal and Fetal Health Research Centre, St Mary s Hospital, Manchester, UK
    Hypertens Pregnancy 30:144-52. 2011
    ..To determine if the phosphodiesterase type 5 inhibitor, sildenafil citrate improves endothelial-dependent relaxation of small arteries from women with preeclampsia...